Latest News for: smarca2

Edit

Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ ...

Nasdaq Globe Newswire 24 Apr 2026
Cambridge, UK, 24th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader ...
Edit

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and

Caledonian Record 21 Apr 2026
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models ....
Edit

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, ...

Norfolk Daily News 21 Apr 2026
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in ... .
Edit

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting (Foghorn Therapeutics Inc)

Public Technologies 21 Apr 2026
ARID1B and SMARCA2 (FHD-909). We are advancing a first-in-class selective enzymatic inhibitor of SMARCA2 in collaboration with Lilly, FHD-909, as well as first-in-class selective ARID1B degraders for ARID1A-mutant cancers.
  • 1

Article Search

tools
×
×
×
×